Flavonoids: An alternative pathway for the treatment of Alzheimer's disease

被引:11
|
作者
Das, Paramita [1 ]
Preethi, K. [1 ]
Kiruba, A. Angelin [1 ]
Nayak, Anjali [1 ]
机构
[1] Krupanidhi Coll Pharm, Dept Pharm, Bangalore 560035, Karnataka, India
来源
关键词
Alzheimer's; Antioxidant; Dementia; Flavonoids; Tau-phosphorylation; OXIDATIVE STRESS; KAEMPFEROL; MORIN; NEUROINFLAMMATION; MECHANISMS; APIGENIN; FISETIN; GINKGO; RUTIN; TAU;
D O I
10.21276/ap.2021.10.2.33
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Alzheimer's is a non-curative disease that occurs in most of the geriatric patients worldwide. It is one of the top 10 diseases which lead to mortality. According to Indian statistics 2020, the average age for symptoms to occur in Alzheimer's is 66-68 years. Patients can survive up to 8 years after the symptoms of dementia. Women are predominant than men. As there is no permanent treatment for Alzheimer's, but medication and management strategies may temporarily improve. On the basis of clinical trials, it can be suggested that single herbs may offer complementary benefits to the approved drugs. Flavonoids are used prophylactically to treat Alzheimer's, as flavonoids are present in most of the fruits, vegetables, and other daily essential products like apple, berries, spinach, red cabbage, onion, dark chocolate, green tea, etc. Flavonoids are also used to treat early symptoms of Alzheimer's like learning and memory loss as flavonoids cross blood-brain barrier (BBB) and prevent tangles. Natural flavonoids mainly possess antioxidant and neuroprotective action which helps to restore damaged brain cells up to a certain extent. Myricetin, morin. rutin, quercetin, fisetin, ginkgo biloba extract, genistein, kaempferol, apigenin, anthocyanin, glycitein are some of the flavonoids used in prevention of Alzheimer's disease. In present study, we discuss different flavonoids to prevent and treat symptoms that are associated with Alzheimer's disease.
引用
收藏
页码:240 / 251
页数:12
相关论文
共 50 条
  • [31] Alternative Aβ Immunotherapy Approaches for Alzheimer's Disease
    Town, Terrence
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2009, 8 (02) : 114 - 127
  • [32] Molecular Aspects of a Diet as a New Pathway in the Prevention and Treatment of Alzheimer's Disease
    Doroszkiewicz, Julia
    Mroczko, Jan
    Rutkowski, Piotr
    Mroczko, Barbara
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (13)
  • [33] Targeting p38 MAPK pathway for the treatment of Alzheimer's disease
    Munoz, Lenka
    Ammit, Alaina J.
    NEUROPHARMACOLOGY, 2010, 58 (03) : 561 - 568
  • [34] Alterations of the Sphingolipid Pathway in Alzheimer’s Disease: New Biomarkers and Treatment Targets?
    Michelle M. Mielke
    Constantine G. Lyketsos
    NeuroMolecular Medicine, 2010, 12 : 331 - 340
  • [35] Alterations of the Sphingolipid Pathway in Alzheimer's Disease: New Biomarkers and Treatment Targets?
    Mielke, Michelle M.
    Lyketsos, Constantine G.
    NEUROMOLECULAR MEDICINE, 2010, 12 (04) : 331 - 340
  • [36] Innovative approaches in acetylcholinesterase inhibition: a pathway to effective Alzheimer's disease treatment
    Arora, Pinky
    Rani, Supriya
    Jha, Sumeet
    Gupta, Sneha
    Kumar, Shubham
    MOLECULAR DIVERSITY, 2025,
  • [37] Treatment of Alzheimer's disease
    Klimkowicz-Mrowiec, Aleksandra
    AKTUALNOSCI NEUROLOGICZNE, 2023, 23 (04): : 145 - 150
  • [38] The treatment of Alzheimer's disease
    Ankri, J
    REVUE NEUROLOGIQUE, 2003, 159 (8-9) : 819 - 824
  • [39] Treatment of Alzheimer's disease
    López, O
    Becker, JT
    REVISTA DE NEUROLOGIA, 2002, 35 (09) : 850 - 859
  • [40] Treatment of Alzheimer's disease
    Browning, CH
    AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (10): : 1460 - 1461